









Markets
/
Stocks
/
nasdaq-nvcr
/

Novocure Ltd

NVCR

12.060USD

+0.050+0.42%

Close 03/13, 16:00（ET）Quotes delayed by 15 min

997.08MMarket Cap

LossP/E TTM



Novocure Ltd

12.060

+0.050+0.42%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Novocure Ltd

Currency: USD Updated: 2026-03-13

Key Insights

Novocure Ltd's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 74 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.93.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Novocure Ltd's Score

Industry at a Glance

Industry Ranking

74 / 208

Overall Ranking

168 / 4554

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Novocure Ltd Highlights

StrengthsRisks

NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 28.67% year-on-year.

Fairly Valued

The company’s latest PE is -9.87, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 94.26M shares, decreasing 15.31% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 1.39M shares of this stock.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

25.929

Target Price

+115.89%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-13

The current financial score of Novocure Ltd is 6.57, ranking 138 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 174.35M, representing a year-over-year increase of 8.11%, while its net profit experienced a year-over-year increase of 62.84%.

Score

Industry at a Glance

Previous score

6.57

Change



Financials

5.99

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.09

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

6.34

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.33

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Novocure Ltd's Company Valuation

Currency: USD Updated: 2026-03-13

The current valuation score of Novocure Ltd is 7.00, ranking 132 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -9.87, which is -39.42% below the recent high of -5.98 and -1261.70% above the recent low of -134.38.

Score

Industry at a Glance

Previous score

7.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 74/208

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-13

The current earnings forecast score of Novocure Ltd is 8.00, ranking 61 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 24.00, with a high of 42.00 and a low of 14.50.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

25.929

Target Price

+115.89%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

115

Total

Median

Average

Company name

Ratings

Analysts

Novocure Ltd

NVCR

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-13

The current price momentum score of Novocure Ltd is 6.84, ranking 64 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 14.78 and the support level at 10.01, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.85

Change

-0.01

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.195

Neutral

RSI(14)

45.903

Neutral

STOCH(KDJ)(9,3,3)

14.743

Sell

ATR(14)

1.223

High Vlolatility

CCI(14)

-102.267

Sell

Williams %R

75.055

Sell

TRIX(12,20)

0.378

Sell

StochRSI(14)

6.498

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

12.470

Sell

MA10

12.986

Sell

MA20

12.563

Sell

MA50

12.705

Sell

MA100

12.620

Sell

MA200

13.511

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-13

The current institutional shareholding score of Novocure Ltd is 7.00, ranking 81 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 84.17%, representing a quarter-over-quarter decrease of 5.46%. The largest institutional shareholder is The Vanguard, holding a total of 10.93M shares, representing 9.61% of shares outstanding, with 4.59% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

16.77M

+0.28%

The Vanguard Group, Inc.

Star Investors

10.43M

-2.76%

BlackRock Institutional Trust Company, N.A.

8.99M

+0.04%

Soleus Capital Management, L.P.

9.64M

+39.69%

Wyss (Hansjorg)

8.14M

State Street Investment Management (US)

2.61M

-2.52%

Geode Capital Management, L.L.C.

2.47M

+1.25%

BlackRock Financial Management, Inc.

2.66M

-2.50%

Quantinno Capital Management LP

1.52M

+11.22%

Risk Assessment

Currency: USD Updated: 2026-03-13

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Novocure Ltd is 5.65, ranking 78 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.76. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.